Search Result

Search Result

Results for "

GD2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibody-Drug Conjugates (ADCs) (1) Apoptosis (1) Biochemical Assay Reagents (2) CD2 (2) CD3 (1) Isotope-Labeled Compounds (1) mTOR (1) PERK (1)
By Research Areas:	Cancer (11) Inflammation/Immunology (2) Neurological Disease (2)

7

Inhibitors & Agonists

10

Inhibitory Antibodies

1

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

Ganglioside GD2 Disialoganglioside GD2	Biochemical Assay Reagents	Cancer
Ganglioside GD2 (Disialoganglioside GD2), a member of the ganglioside family, is a tumor-associated antigen that is highly expressed in almost all neuroblastomas, as well as in most melanomas and retinoblastomas. Ganglioside GD2 contributes to tumor development by enhancing cell proliferation, motility, migration, adhesion, and invasion. Anti-Ganglioside GD2 strategies hold promise for research in the field of anti-tumor therapy .

M3554	Antibody-Drug Conjugates (ADCs) CD2	Cancer
M3554 is a novel anti-GD2 ADC designed based on humanized ch14.18 anti-GD2 antibody and has anti-tumor activity. The cytotoxicity of M3554 against the GD2-positive neuroblastoma cell line CHP134 was in the subnanomolar IC₅₀ range.

Nivatrotamab Hu3F8-BsAb	CD2 CD3	Cancer
Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma .

Dinutuximab APN-311	Apoptosis PERK mTOR	Cancer
Dinutuximab (APN-311) is a chimeric human-mouse *anti-GD2* monoclonal antibody. Dinutuximab can bind to *GD2* on the cell surface, triggering antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and promoting tumor regression. Dinutuximab can inhibit the growth, invasion, and migration and induce apoptosis of tumor cells. Dinutuximab can be used in the research of tumors such as neuroblastoma and breast cancer ^[2] .

*C18:0-d7 GD2* Ceramide (d18:1/18:0-d7)**	Isotope-Labeled Compounds	Others
C18:0-d₇ GD2 Ceramide (d₁₈:1/18:0-d₇) is deuterium labeled C18:0 GD2 Ceramide (d18:1/18:0) .

beta-1,4-N-Acetylgalactosaminyltransferase (CgtA) GM2/GD2 synthase	Others	Neurological Disease
beta-1,4-N-Acetylgalactosaminyltransferase (CgtA) (GM2/GD2 synthase) is a key enzyme which catalyzes the conversion of GM3, GD3 and lactosylceramide (LacCer) to GM2, GD2 and asialo-GM2 (GA2), respectively. beta-1,4-N-Acetylgalactosaminyltransferase (CgtA) is a key enzyme to control the synthesis of brain-enriched complex gangliosides .

NM600	Biochemical Assay Reagents	Neurological Disease Inflammation/Immunology Cancer
NM600 is an alkylphosphocholine mimetic RPT agent. NM600 demonstrates an antitumor activity against a second GD2+ neuroblastoma xenograft model with SY5Y cells. NM600 can enhance suboptimal CAR T cell efficacy against solid tumors. NM600 can be studied in research for neuroblastoma .

Cat. No.	Product Name	Target	Research Area

*Anti-Ganglioside GD2* Antibody (14G2a)**	Inhibitory Antibodies	Others
Anti-Ganglioside GD2 Antibody (14G2a) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human Ganglioside GD2. The recommend isotype control of Anti-Ganglioside GD2 Antibody (14G2a): Mouse IgG2a kappa, Isotype Control (HY-P99978).

Naxitamab Naxitamab-gqgk; Humanized 3F8; Hu3F8	Inhibitory Antibodies	Cancer
Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers .

Nivatrotamab Hu3F8-BsAb	CD2 CD3	Cancer
Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma .

Lorukafusp alfa APN-301; hu14.18-IL2; EMD 273063	Inhibitory Antibodies	Cancer
Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity .

Dinutuximab APN-311	Apoptosis PERK mTOR	Cancer
Dinutuximab (APN-311) is a chimeric human-mouse *anti-GD2* monoclonal antibody. Dinutuximab can bind to *GD2* on the cell surface, triggering antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and promoting tumor regression. Dinutuximab can inhibit the growth, invasion, and migration and induce apoptosis of tumor cells. Dinutuximab can be used in the research of tumors such as neuroblastoma and breast cancer ^[2] .

hu14.18 (K322A)	Inhibitory Antibodies	Cancer
hu14.18 (K322A) is a humanized anti-disialoganglioside GD2 monoclonal antibody that contains fully human amino acid sequences for immunoglobulin G1 heavy and kappa light chains. hu14.18 (K322A) has antibody-dependent cellular cytotoxicity (ADCC). hu14.18 (K322A) can be used for the study of high-risk neuroblastoma .

MORAb-028	Inhibitory Antibodies	Cancer
MORAb-028 is a humanized IgM monoclonal antibody inhibitor targeting *GD2. MORAb-028 has a potent antitumor activity and kills GD2*-expressing target cells via complement-mediated cytotoxicity (CDC). MORAb-028 significantly inhibits tumor growth in EL-4-luc xenograft mice model. MORAb-028 can be used for melanoma cancer research .

Naxitamab (Mouse IgG1)	Inhibitory Antibodies	Cancer
Naxitamab (Hu3F8) (Mouse IgG1) is a mouse-derived IgG1 monoclonal antibody targeting the *diazoglycoside GD2* (hu3F8)*. Naxitamab can be used in the research of neuroblastoma, osteosarcoma, and other GD2*-positive cancers .

Donitabart	Inhibitory Antibodies	Inflammation/Immunology
HY-P990916 is an ganglioside GD2-targeting IgG1κ type chimeric humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .

Daretabart	Inhibitory Antibodies	Cancer
Daretabart is a humanized IgG1K antibody targeting *GD2*, which can be used for anti-tumor research. The corresponding isotype control is: Human lgG1 kappa, lsotype Control (HY-P99001) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

MedChemExpress Magic Cece

MedChemExpress: Contact Us; About Us; Headquarters; Distributors; Statement on False Report; Careers

Customer Support: Technical Support; Service; Ordering Information; Easy Return; Shipping Rates & Policies; Intellectual Property Promise

Resources: Free Sample; Resources; Molarity Calculator; Dilution Calculator; Terms & Conditions; Reconstitution Calculator; Specific Activity Calculator; DNA/RNA sequence conversion tools

Subscribe to our E-newsletter

Name
Email *

	Sorry, but the email address you supplied was invalid.

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.

Copyright © 2013-2025 MedChemExpress. All Rights Reserved.: Site Map Privacy Policy

Join with us